PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...
Baird analyst Joe Vruwink raised the firm’s price target on PTC (PTC) to $228 from $226 and keeps an Outperform rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback